Special Issue

Nanomedicine and Nanosensors in Cancer Therapies

Message from the Guest Editors

Nanomedicine focuses on the effect of nanomaterials in biological systems to achieve a more efficient therapy or increase the accuracy of diagnosis. Cancer is a leading cause of death worldwide. Nanotechnology studies have, thus far, showed successful results for cancer therapy and diagnosis. Nanomedicine can be classified as a material with at least one nanometric component. which can include metallic nanoparticles, polymeric nanoparticles, graphene and others. This Special Issue aims to shed light on the current state of the art of nanomedicine in cancer therapy. We invite articles on all aspects of drug targeting, pharmacokinetics and pharmacodynamics. Manuscripts regarding issues such as multiple-drug resistance tumors and a combination of nanomaterials and chemotherapy and radiotherapy agents will be highlighted.

Guest Editors

Dr. Milena Trevisan Pelegrino

- Institute of Environmental, Chemical and Pharmaceutical Sciences (ICAQF), Federal University of São Paulo (UNIFESP), São Paulo, Brazil
 Center for Natural and Human Sciences, Federal University of ABC, Santo André, São Paulo 09210-580, Brazil
- 3. Mirscience Therapeutics, São Paulo, São Paulo 05653-000, Brazil

Dr. Amedea B. Seabra

Center for Natural and Human Sciences (CCNH), Federal University of ABC (UFABC), Av. dos Estados, 5001-Bangú, Santo André 09210-580, SP, Brazil

Deadline for manuscript submissions

closed (25 February 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/87589

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

